Source: Treatment.com
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Treatment.com International Inc. (TRUE) symptom assessment tool is available on Google Play Store after a successful launch
  • Treatment Digital Health App is a doctor-built app and is driven by an intelligent digital health assistant
  • The app will provide access to advanced medical knowledge for widespread use
  • Doctors currently use Treatment’s AI software for their clinical assessments globally
  • Treatment.com International Inc. (TRUE) is down 3.23 per cent and is trading at $0.60 per share as of 12:07 p.m. EST

Treatment.com International Inc. (TRUE) symptom assessment tool, Treatment Digital Health App, is available on Google Play Store after a successful launch on the Apple App Store.

Treatment Digital Health App is a doctor-built app and is driven by an intelligent digital health assistant to allow people to take control of their health.

The app is powered by Treatment’s proprietary medical AI engine and its Global Library of Medicine (GLM). The app will provide access to advanced medical knowledge for widespread use.

The app’s health assessments aim to surpass the user’s expectations using up-to-date estimates of disease rates, current estimates of geographic variation, and the latest medical research.

Doctors currently use Treatment’s AI software to provide information for their clinical assessments globally. The same technology is used by leading medical schools to test students’ clinical skills.

John Fraser, CEO of Treatment.com, stated,

“We’ve been pleased to receive overwhelmingly positive reviews on the Apple App Store for our first-even product launch, including from qualified sources like medical doctors… we are confident that this launch on the Google Play Store will go a huge step further towards fulfilling the growing, global need for up-to-date, credible health information,”
Treatment.com is a Vancouver-based healthcare technology company that is harnessing the power of AI to help global citizens improve their health through personalized recommendations and insights. 

Treatment.com International Inc. (TRUE) is down 3.23 per cent and is trading at $0.60 per share as of 12:07 p.m. EST.

More From The Market Herald
Knight Therapeutics - President and CEO, Samira Sakhia.

" Knight Therapeutics (TSX:GUD) relaunches AKYNZEO in Brazil

Knight Therapeutics’ (GUD) affiliate United Medical has relaunched AKYNZEO in Brazil.
GameOn - Founder and CEO, Matt Bailey.

" GameOn (CSE:GET) receives US$560,000 loan

GameOn Entertainment Technologies (GET) has obtained a US$560,000 loan from Proje Ventures Inc. 

" RIWI Corp. (TSXV:RIWI) acquires Research on Mobile

RIWI Corp. (RIWI) has completed its previously announced acquisition of Research on Mobile (ROM).

" Record revenue for California Nanotechnologies (TSXV:CNO) fiscal 2022

California Nanotechnologies (CNO) announced record revenues of US$1,081,500 for the year ending February 28, 2022, a 39 per cent increase from last year.